Qube Research & Technologies LTD I Mab Transaction History

Qube Research & Technologies LTD

$61.9 Billion
Q1 2024

A detailed history of Qube Research & Technologies LTD transactions in I Mab stock. As of the latest transaction made, Qube Research & Technologies LTD holds 4,065 shares of IMAB stock, worth $6,422. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,065

Previous 2,168 87.5%

Holding current value

$6,422

Previous $4,000 75.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$1.54 - $2.37 $2,921 - $4,495	1,897 Added 87.5%	4,065 $7,000
Q4 2023 Feb 13, 2024	BUY	$1.21 - $1.9 $696 - $1,094	576 Added 36.18%	2,168 $4,000
Q3 2023 Nov 13, 2023	SELL	$1.18 - $3.06 $52,230 - $135,444	-44,263 Reduced 96.53%	1,592 $2,000
Q2 2023 Aug 14, 2023	SELL	$2.95 - $3.85 $309,950 - $404,511	-105,068 Reduced 69.62%	45,855 $137,000
Q1 2023 May 15, 2023	BUY	$3.08 - $7.39 $135,935 - $326,157	44,135 Added 41.33%	150,923 $522,000

Q4 2022 Feb 14, 2023	SELL	$3.22 - $4.86 $192,427 - $290,433	-59,760 Reduced 35.88%	106,788 $446,000
Q3 2022 Nov 14, 2022	BUY	$4.01 - $12.34 $667,857 - $2.06 Million	166,548 New	166,548 $668,000
Q2 2022 Aug 15, 2022	SELL	$8.27 - $18.43 $847,410 - $1.89 Million	-102,468 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$12.54 - $46.93 $370,331 - $1.39 Million	29,532 Added 40.49%	102,468 $1.66 Million
Q4 2021 Feb 01, 2022	BUY	$45.28 - $74.5 $3.3 Million - $5.43 Million	72,936 New	72,936 $3.46 Million
Q2 2021 Aug 13, 2021	SELL	$47.86 - $83.95 $2.01 Million - $3.53 Million	-42,099 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$44.38 - $63.97 $1.87 Million - $2.69 Million	42,099 New	42,099 $2.04 Million

Others Institutions Holding IMAB

# of Institutions

Shares Held

16M

Call Options Held

11.9K

Put Options Held

3.5K

View Full List

About I-Mab

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $131M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

More about IMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.

Account

Qube Research & Technologies LTD I Mab Transaction History